Search Results
Your search for ,ITS matches 8694 pages
Showing 4051 - 4100Neurologic Knowledge to Enhance Well-Being and Happiness
BOOKMARK Title: Your Happy Brain: Why and How to Hug ItAuthors: Philomena Lawrence, BA, BEd, and Gilbert Lawrence, MD, FRCRPublisher: CreateSpace Independent Publishing PlatformPublication date: June 2018Price: $16.00, paperback, 390 pages Some 2,400 years ago, the ancient Greeks were among the...
St. Baldrick’s Foundation Grants Institutional Funding for Clinical Trials Research in Children With Cancer
To grant more children with cancer access to clinical trials, the St. Baldrick’s Foundation has awarded 29 infrastructure grants totaling $1.7 million to institutions across the country. This series of grants brings the St. Baldrick’s Foundation’s funding total to more than $26 million awarded in...
A Diagnosis of Li-Fraumeni Syndrome Has Focused My Life Direction
Despite the fact that I had to have open heart surgery at age 7 to fix a congenital heart defect and then more surgery, chemotherapy, and radiation therapy to treat a diagnosis of rhabdomyosarcoma a year later, I never felt like I was a sick kid. Children don’t have the existential worries about...
A Feminist Take on Health-Care Disparities
BOOKMARK Title: Doing Harm: The Truth About Bad Medicine and Lazy Science Leave Women Dismissed, Misdiagnosed, and SickAuthor: Maya DusenberyPublisher: HarperOnePublication date: March 2018Price: $27.99, hardcover, 400 pages Over the past year or so, there have been several books by women focused...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
The Skin Cancer Foundation Raises $600,000 at Gala
The Skin Cancer Foundation recently held its 22nd annual Gala at The Plaza Hotel in New York. The Champions for Change Gala is the Foundation’s signature fundraising event, and $600,000 was raised to support the organization’s educational campaigns, community programs, and research initiatives....
Pembrolizumab With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC
On August 20, 2018, pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum was granted regular approval as first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma...
Addressing Patient Expectations Regarding the Use of Alternative Therapies
Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York. GUEST EDITOR The ASCO Post’s Integrative Oncology series is intended to facilitate the...
The Chemotherapy Foundation Innovation Gala
This year marks the 50th anniversary of the launch of The Chemotherapy Foundation. Founded by Ezra M. Greenspan, MD, in 1968, with the goal of advancing effective cancer treatments, The Chemotherapy Foundation helped propel the modern era of chemotherapy and the later development of targeted...
Artificial Intelligence–Based Smartphone App Decreases Pain and Reduces Inpatient Hospitalizations in Patients With Cancer
A smartphone application utilizing elements of artificial intelligence was associated with improved cancer pain outcomes and a significant reduction in pain-related hospital admissions, according to data presented at the 2018 Palliative and Supportive Care in Oncology Symposium.1 Results of the...
Padmanee Sharma, MD, PhD, Receives Pandolfi Award for Women in Cancer Research
Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, has been recognized for her contributions to the field of immuno-oncology with the Pandolfi Award for Women in Cancer Research at the 11th Annual Beth Israel Deaconess Medical Center Cancer Symposium. Dr. Sharma was...
The Politics and Economics of Cancer Prevention
Finance is a key driver in cancer prevention, as has been evidenced by the influence of tax on the consumption of products such as cigarettes and alcohol. Going up against a huge industry like Big Tobacco will almost certainly be met with tremendous opposition, but understanding the industrial...
Unequal Burden of Cancer-Related Suffering and Need for Palliative Care
The global burden of cancer-related suffering is tremendously unbalanced, according to Eric L. Krakauer, MD, PhD, Director of the Global Palliative Care Program at Massachusetts General Hospital and Harvard Medical School, Boston and a lead coauthor of the Report of the Lancet Commission on Global...
SABCS 2018: Delayed Initiation of Adjuvant Chemotherapy Associated With Worse Outcomes in Patients With Triple-Negative Breast Cancer
A retrospective study evaluating the influence of time to chemotherapy on patients with triple-negative disease and its impact on survival outcome has found that patients who delayed adjuvant chemotherapy more than 30 days after surgery had a significantly higher risk for disease recurrence and...
Global Burden of Cancer on the Rise: Implications for Cancer Prevention and Control
As the global burden of cancer grows, cancer control measures must be tailored to regional and national priorities, underscoring the need for high-quality cancer registries, according to Christopher P. Wild, PhD, Director of the International Agency for Research on Cancer in Lyon, France. Earlier...
ASH 2018: Researchers Identify Mutation in BCL2 Protein That Causes Resistance to Venetoclax in Progressive CLL
Investigators from Australia have identified a genetic mutation that causes resistance to the targeted drug venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL), according to research presented by Blombery et al at the 2018 American Society of Hematology (ASH) Annual Meeting...
ASH 2018: CASSINI Trial: Rivaroxaban Thromboprophylaxis for VTE Prevention in Patients With Cancer
A new study suggests taking a direct oral anticoagulant (DOAC) can reduce the risk of harmful blood clots in patients undergoing cancer treatments, without substantially increasing the risk of bleeding problems. Findings from the CASSINI trial were presented by Khorana et al at the 2018 American...
ASH 2018: Update of ZUMA-1: Axicabtagene Ciloleucel in DLBCL
A follow-up analysis of patients enrolled in the multicenter ZUMA-1 trial for diffuse large B-cell lymphoma (DLBCL) showed axicabtagene ciloleucel can induce durable responses, yield a median overall survival of more than 2 years, and has a manageable long-term safety profile. Axicabtagene...
ASH 2018: Checkpoint Inhibitors Plus CAR T-Cell Therapy in Relapsed ALL
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has been shown to be effective in patients with relapsed B-cell acute lymphocytic leukemia (B-ALL). However, in some patients, the antitumor effects of CAR T-cell treatment are short-lived, which may, in part, be caused by a reaction of...
ASH 2018: Large Single-Arm Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
The largest prospective trial of hydroxyurea for sickle cell anemia (SCA) has shown that this treatment—long the standard of care for treating SCA in developed countries—is feasible, accepted, well tolerated, and safe for children living in sub-Saharan Africa. Tshilolo et al reported...
Dissemination of Misleading Information on Prostate Cancer on Social Media
YouTube videos on prostate cancer often offer misleading or biased medical information that poses potential health risks to patients, an analysis of the social media platform published by Loeb et al in European Urology showed. For the latest analysis, researchers, which included social...
Phase III Trial of Minimally Invasive vs Open Abdominal Radical Hysterectomy in Early Cervical Cancer
In a phase III trial (Laparoscopic Approach to Cervical Cancer [LACC]) reported in The New England Journal of Medicine, Ramirez et al found that minimally invasive radical hysterectomy was associated with poorer disease-free and overall survival vs open abdominal radical hysterectomy in women with...
FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions
On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (Vitrakvi) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, whose...
A Single CAR T Cell Cured My Chronic Lymphocytic Leukemia
The combination of symptoms I began experiencing in the spring of 2007, including night sweats so severe they woke me from a sound sleep and midline chest wall swelling so extreme I needed a larger shirt size, drove me to seek immediate medical attention. A series of imaging and blood tests...
Obligation to Evaluate Racial/Ethnic Features That May Affect Outcomes for Patients With Breast Cancer
"WE ABSOLUTELY have an obligation to evaluate all of the features describing our patients with cancer when we are trying to figure out why some patients do better than others,” Lisa A. Newman, MD, MPH, reminded the nearly 700 participants at the 2018 Lynn Sage Breast Cancer Symposium, hosted by...
A Pediatric Oncologist Recounts 7 Years at a Hospital in Jerusalem
Elisha Waldman, MD, is a pediatric oncologist and Associate Chief in the Division of Palliative Care at the Ann and Robert H. Lurie Children’s Hospital in Chicago. He grew up in a Connecticut suburb, the son of a conservative rabbi. Early on, Dr. Waldman majored in religious studies and felt...
Founder of the Harvard Stem Cell Institute Relates the History of Cancer Research
Cancer memoirs are generally written by people who have an intimate relationship with the disease, mostly survivors, sometimes by those who are dying while writing, such as the breathtaking book, The Bright Hour: A Memoir of Living and Dying, by the poet Nina Riggs. Once in a while, a scientist or...
Probiotics
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, explore some of the beneficial effects attributed ...
Nivolumab for Third-Line Treatment of Metastatic Small Cell Lung Cancer
ON AUGUST 16, 2018, nivolumab (Opdivo) was granted accelerated approval for treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression after platinum-based chemotherapy and at least one other line of therapy.1,2 Supporting Efficacy Data APPROVAL WAS BASED on...
Focus on the Rocky Mountain Oncology Society
Formed in 1991, the Rocky Mountain Oncology Society (RMOS), a Chapter Member of the Association of Community Cancer Centers (ACCC) and State Affiliate of ASCO, serves as the voice for Colorado’s multidisciplinary cancer care teams and the patients they serve. Representing the common interests of...
ASH Honors Cage S. Johnson, MD, and José A. López, MD, With Award for Leadership in Promoting Diversity
DURING THE 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December, ASH will honor Cage S. Johnson, MD, Professor Emeritus of Medicine, Physiology, and Biophysics at the University of Southern California, and José A. López, MD, Professor of Medicine...
When Illness and Culture Collide
“‘Sickness’ is what is happening to the patient. Listen to him. Disease is what is happening to science and to populations.” —Lawrence Weed, MD, 1978 America’s massive health-care system is highly complex, with its own unique language, methods, technologies, and scientific approaches, developed and ...
Electronic ‘Datarrhea’ and Wellness
THE INTRODUCTION of the electronic health record (EHR) was supposed to lead us to a utopian world for health-care delivery in America. The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, promoted its implementation by providing financial incentives.1 The Centers for...
A Career Path Shaped by Unlimited Possibilities for Clifford A. Hudis, MD, FACP, FASCO
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed Clifford A. Hudis, MD, FACP, FASCO, ASCO’s Chief Executive Officer. Prior to his current position, Dr. Hudis served in a variety of roles at ASCO, including President during ASCO’s 50th anniversary...
California Researchers Receive $4.5 Million to Develop Immunotherapies in Head and Neck Cancer
RESEARCHERS AT LA JOLLA INSTITUTE for Immunology and University of California (UC), San Diego, have been awarded $4.5 million as part of the National Cancer Institute’s Cancer Moonshot initiative. The funding will support research to develop new and improved immunotherapeutic options for patients...
FDA Expands Approved Use of Brentuximab Vedotin in Some Types of PTCL
ON NOVEMBER 16, 2018, the U.S. Food and Drug Administration (FDA) expanded the approved use of brentuximab vedotin (Adcetris) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL)—adults with previously untreated systemic anaplastic...
New Leadership Elected to ASH Executive Committee
THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH Annual Meeting & Exposition in December. Martin S. Tallman, MD, will serve a 1-year term as Vice President, followed by successive terms as...
FDA Approves Glasdegib for Patients With Newly Diagnosed AML Who Cannot Undergo Intensive Chemotherapy
Today, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo) tablets to be used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or with comorbidities that may preclude the use of ...
ASCO President-Elect Candidates Identify Key Issues Facing the Field of Oncology
Lori J. Pierce, MD, FASTRO, FASCO, of the University of Michigan, and Carolyn D. Runowicz, MD, FASCO, of Herbert Wertheim College of Medicine, Florida International University, Miami, were selected by the ASCO Nominating Committee as candidates for President-Elect. Why do you want to serve as ASCO...
Cemiplimab-rwlc for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
On September 28, 2018, cemiplimab-rwlc (Libtayo) was approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.1 Supporting Efficacy Data Approval...
Patients With Cancer in Rural America Remain Underserved
Despite growing national awareness of health-care inequities, the plight of rural Americans diagnosed with cancer has persistently remained inadequate. Speaking with The ASCO Post, Jan Probst, PhD, Professor at the Arnold School of Public Health, University of South Carolina, Columbia, noted, “We...
Duvelisib in Resistant Chronic Lymphocytic Leukemia: Expanding the Treatment Armamentarium
The phase III DUO trial, reported by Flinn et al and reviewed in this issue of The ASCO Post, has led to the U.S. Food and Drug Administration (FDA) approval of a novel B-cell receptor (BCR) kinase inhibitor, duvelisib (Copiktra), which targets phosphoinositide 3-kinase (PI3K)-δ/γ in patients...
Parenteral Opioid Shortage Threatens Appropriate Pain Care for Patients With Cancer
In response to the opioid-overdose epidemic, several measures have been put in place, such as the reclassification of hydrocodone as a Schedule II opioid and new requirements for physician review of prescription drug–monitoring program databases in most states. Moreover, the Surgeon General and...
Undertreatment of High-Risk Prostate Cancer in Latino Men
New research by Lichtensztajn et al in JNCCN—Journal of the National Comprehensive Cancer Network examined disparities in care for Latino men with prostate cancer. A team of researchers from UCSF Helen Diller Family Comprehensive Cancer Center, Stanford Cancer Institute, and...
Atlantic Health System Announces Collaboration to Further Patient Access to Innovative Cancer Therapies
The Atlantic Health System, an integrated health-care delivery system, recently announced a partnership with the Translational Genomics Research Institute, an affiliate of City of Hope, and Origin Commercial Ventures to create a new platform to deliver economically viable immunotherapies and other...
Study Identifies Suitable Partner for Bevacizumab in Recurrent Ovarian Cancer
For patients with recurrent ovarian cancer who receive platinum-based retreatment, the more suitable partner for bevacizumab (Avastin) may be carboplatin plus pegylated liposomal doxorubicin, rather than carboplatin and gemcitabine, according to the results of a phase III ENGOT/GCIG Intergroup...
Expert Point of View: Caroline Robert, MD, PhD
The paper’s invited discussant, Caroline Robert, MD, PhD, of the Institut de Cancérologie Gustave Roussy, Villejuif, France, said OpACIN-neo attained its goal of reducing toxicity and maintaining efficacy. The regimen of two courses of ipilimumab (Yervoy) at 1 mg/kg plus nivolumab (Opdivo) at 3...
Pembrolizumab Improves Survival in Advanced Head and Neck Cancer
An overall survival advantage has now been shown for first-line immunotherapy in recurrent or metastatic head and neck cancer, researchers reported at the European Society for Medical Oncology (ESMO) 2018 Congress.1 In the phase III KEYNOTE-048 trial, treatment with the anti–programmed cell death...
Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC
In a global phase II study reported in The Lancet Oncology, Solomon et al found that lorlatinib (Lorbrena) showed high overall and intracranial activity in patients with advanced ALK-positive non–small cell lung cancer (NSCLC) who were treatment-naive or who had received crizotinib (Xalkori)...
Dealing With the Challenges Presented by the Parenteral Opioid Shortage
The opioid drug problem in the United States is a crisis, with unprecedented numbers of overdose deaths. The reaction to this has resulted in new federal laws and regulations aimed at restricting overuse and overprescribing of opioids. However, these well-intentioned actions, along with other...
